Aprea Therapeutics shares surge 101.69% intraday after reporting early clinical proof-of-concept with partial response in endometrial cancer trial.

Aprea Therapeutics surged 101.69% intraday following two key announcements on January 29, 2026. The company reported early clinical proof-of-concept in its ACESOT-1051 trial for WEE1 inhibitor APR-1051, with a patient showing a 50% reduction in target lesions and a 90% decrease in CA-125 levels. Simultaneously, Aprea secured $5.6 million through a private placement at $0.89 per share, priced at-the-market, to fund its trials and extend cash runway into Q1 2027. These developments—positive clinical data and secured financing—significantly boosted investor confidence, driving the sharp intraday price increase.